Research progress on the role of Cyclin D1 in endocrine therapy resistance of breast cancer
10.12354/j.issn.1000-8179.2025.20250718
- VernacularTitle:Cyclin D1在乳腺癌内分泌治疗耐药中的作用研究进展
- Author:
Wang TONG
1
;
Cui QI
1
;
Wang YILIN
1
;
Zhao JING
1
Author Information
1. 天津医科大学肿瘤医院乳腺肿瘤二科,国家恶性肿瘤临床医学研究中心,天津市恶性肿瘤临床医学研究中心,乳腺癌防治教育部重点实验室,天津市"肿瘤防治"重点实验室(天津市 300060)
- Publication Type:Journal Article
- Keywords:
Cyclin D1;
breast cancer;
endocrine therapy resistance
- From:
Chinese Journal of Clinical Oncology
2025;52(17):892-896
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer has emerged as the leading cause of cancer incidence and mortality among women globally,with approximately 70%of cases being estrogen receptor(ER)and/or progesterone receptor(PR)positive.The primary treatment for hormone receptor(HR)positive breast cancer is endocrine therapy;however,endocrine therapy resistance remains a critical area of ongoing research.Cyclin D1 is recognized as a biomarker for tumor phenotype and disease progression,and it has been established to correlate with the onset,progres-sion,and prognosis of breast cancer.Recently,studies have also reported the significant role of Cyclin D1 in endocrine resistance in breast cancer.This article provides an overview of the research progress on Cyclin D1 in breast cancer,with a particular emphasis on its relation-ship with endocrine therapy resistance,aiming to offer novel insights for the endocrine treatment of breast cancer.
